Robert Gould

Robert is an Operating Partner at Khosla Ventures where he advises healthcare companies.

Prior to joining KV, Robert was president and CEO of Fulcrum Therapeutics from its founding in 2016 until 2021. Previously, he served as president and CEO of Epizyme, an oncology drug discovery and development company, and prior to that, he was director of novel therapeutics at Broad Institute of MIT and Harvard. Robert began his career at Merck, where for more than 23 years he held a variety of leadership positions, culminating in the role of vice president for licensing and external research.

During his career, Robert has been instrumental in advancing more than 20 compounds from discovery to clinical development in multiple therapeutic areas, several of which have been life-changing for patients.

Currently, he serves on the boards of Faeth Therapeutics, Fulcrum Therapeutics, Turnstone Biologics, HemoShear Therapeutics and Spring Arbor University.

Robert holds a bachelor’s degree in chemistry from Spring Arbor University and a Ph.D. in biochemistry from the University of Iowa. He completed postdoctoral studies at Johns Hopkins University.